Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celon Pharma SA

www.celonpharma.com

Latest From Celon Pharma SA

Glenmark Re-Evaluates Complex Generics Basket, Won’t Be Part Of The 'Crowd'

Glenmark has ended development of certain in-licensed complex generic assets including generic versions of Abraxane and Suboxone in view of the extremely competitive landscape in the US. The Indian firm says it would rather focus on products where it is an early entrant.

India Commercial

Glenmark Re-Evaluates Complex Generics Basket, Won’t Be Part Of The 'Crowd'

Glenmark has ended development of certain in-licensed complex generic assets including generic versions of Abraxane and Suboxone in view of the extremely competitive landscape in the US. The Indian firm says it would rather focus on products where it is an early entrant.

India Commercial

Can Glenmark-Celon’s Generic Seretide DPI Break Into Germany?

Glenmark-Celon’s generic version of GlaxoSmithKline’s Seretide Accuhaler dry powder inhaler (DPI) has received the go ahead in Germany, upping the competition quotient in a significant market that has generally been seen as tough to penetrate.

 

Respiratory Generic Drugs

Can Glenmark-Celon’s Generic Seretide DPI Break Into Germany?

Glenmark-Celon’s generic version of GlaxoSmithKline’s Seretide Accuhaler dry powder inhaler (DPI) has received the go ahead in Germany, upping the competition quotient in a significant market that has generally been seen as tough to penetrate.

 

Respiratory Generic Drugs
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Eastern Europe
        • Poland
  • Parent & Subsidiaries
  • Celon Pharma SA
  • Senior Management
  • Maciej Wieczorek, PhD, CEO
  • Contact Info
  • Celon Pharma SA
    Phone: 22 751 59 33
    Ogrodowa 2A
    Lomianki, 05-092
    Poland
Advertisement
Advertisement
UsernamePublicRestriction

Register